/NVNO
NVNO Stock - enVVeno Medical Corporation
Healthcare|Medical - DevicesNASDAQ
$0.32-7.75%
$0.03 (-7.75%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.35
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVNO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.32 – $0.32
TARGET (TP)$0.37
STOP LOSS$0.29
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.07
52W High$5.62
52W Low$0.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-528,000 | $-546,000 | $-525,000 | $-452,909 | $-383,972 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-23,826,000 | $-25,238,000 | $-24,932,000 | $-16,892,503 | $-9,135,126 |
| Net Income | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,527,822 | $-9,135,486 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.27 | $-1.91 | $-2.20 | $-1.90 | $-7.54 |
Company Overview
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NVNOBeat Rate
56%
Last 18 quarters
Avg Surprise
-22.9%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$-0.23
Q4 2025
EPS Surprise History
Q1 24
+30.4%
$-0.32vs$-0.46
Q2 24
+22.5%
$-0.31vs$-0.40
Q3 24
+13.9%
$-0.31vs$-0.36
Q4 24
-6.1%
$-0.35vs$-0.33
Q1 25
+14.3%
$-0.30vs$-0.35
Q2 25
+35.3%
$-0.22vs$-0.34
Q3 25
-17.9%
$-0.33vs$-0.28
Q4 25
+23.3%
$-0.23vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q4 2025 | Oct 31, 2025 | $-0.30 | $-0.23 | +23.3% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.28 | $-0.33 | -17.9% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $-0.34 | $-0.22 | +35.3% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.35 | $-0.30 | +14.3% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.33 | $-0.35 | -6.1% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $-0.36 | $-0.31 | +13.9% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.40 | $-0.31 | +22.5% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.46 | $-0.32 | +30.4% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $-0.48 | $-0.45 | +6.2% | ✓ BEAT |
Q3 2023 | Jul 31, 2023 | $-0.49 | $-0.58 | -18.4% | ✗ MISS |
Q2 2023 | May 1, 2023 | $0.48 | $-0.57 | -218.7% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.57 | $-0.55 | +3.5% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $-0.52 | $-0.54 | -3.8% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-0.33 | $-0.63 | -90.9% | ✗ MISS |
Q2 2022 | Apr 29, 2022 | $-0.29 | $-0.47 | -62.1% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.33 | $-0.94 | -184.8% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.34 | $-0.26 | +23.5% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.34 | $-0.28 | +17.6% | ✓ BEAT |
Latest News
Trading Halt: Halt status updated at 5:25:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 13, 2025, 10:25 PM
enVVeno Receives Unfavorable Decision From FDA In Response To Supervisory Appeal Of Not-Approvable Letter It Received On August 19 In Response To PMA Application For VenoValve
📉 NegativeBenzinga•Nov 13, 2025, 10:09 PM
Trading Halt: Halted at 4:55:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 13, 2025, 09:55 PM
enVVeno Medical Q3 EPS $(0.23) Beats $(0.30) Estimate
📈 PositiveBenzinga•Oct 31, 2025, 01:26 PM
enVVeno Medical To File Supervisory Appeal After FDA Rejects VenoValve Premarket Approval Application
📉 NegativeBenzinga•Sep 15, 2025, 12:47 PM
EnVVeno Medical shares are trading lower after the company on Wednesday announced the FDA has not approved its VenoValve PMA submission.
📉 NegativeBenzinga•Aug 21, 2025, 04:58 PM
enVVeno tanks after FDA rejects VenoValve approval
📉 NegativeSeeking Alpha•Aug 20, 2025, 02:55 PM
EnVVeno Medical shares are trading lower after the company announced the FDA has not approved its VenoValve PMA submission.
📉 NegativeBenzinga•Aug 20, 2025, 12:27 PM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Aug 20, 2025, 11:25 AM
enVVeno Medical Announces FDA Not-Approvable Decision On VenoValve PMA Submission
📉 NegativeBenzinga•Aug 20, 2025, 11:09 AM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 20, 2025, 10:55 AM
Frequently Asked Questions about NVNO
What is NVNO's current stock price?
enVVeno Medical Corporation (NVNO) is currently trading at $0.32 per share. The stock has moved -7.75% today.
What is the analyst price target for NVNO?
No analyst price targets are currently available for this stock.
What sector is enVVeno Medical Corporation in?
enVVeno Medical Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is NVNO's market cap?
enVVeno Medical Corporation has a market capitalization of $0.01 billion, making it a small-cap company.
Does NVNO pay dividends?
No, enVVeno Medical Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADGM
Adagio Medical Holdings, Inc.
$1.03
Mkt Cap: $0.0B
AEMD
Aethlon Medical, Inc.
$2.86
Mkt Cap: $0.0B
ALUR
Allurion Technologies Inc.
$1.47
Mkt Cap: $0.0B
AYTU
Aytu BioPharma, Inc.
$2.55
Mkt Cap: $0.0B
COCH
Envoy Medical, Inc.
$0.73
Mkt Cap: $0.0B
CODX
Co-Diagnostics, Inc.
$0.26
Mkt Cap: $0.0B
EKSO
Ekso Bionics Holdings, Inc.
$4.86
Mkt Cap: $0.0B
GOVX
GeoVax Labs, Inc.
$0.16
Mkt Cap: $0.0B
PRPH
ProPhase Labs, Inc.
$0.09
Mkt Cap: $0.0B
VVOS
Vivos Therapeutics, Inc.
$1.97
Mkt Cap: $0.0B
Explore stocks similar to NVNO for comparison